Kuano.ai

Kuano.ai, under the leadership of co-founder Dr. Vid Stojevic, combines quantum physics, artificial intelligence (AI), and medicinal chemistry to explore enzyme inhibition therapies. The company is utilizing its platform to advance a pipeline of new therapies for unmet medical needs, as well as collaborative projects with leading academic and commercial partners. This includes a recent collaboration with the Alzheimer's Research UK UCL Drug Discovery Institute to identify inhibitors for degenerative neurological diseases. Our discovery platform uniquely integrates target quantum mapping with AI-driven chemistry, enabling the faster development of better drug candidates. Our distinctive approach addresses common challenges in AI-driven drug design and target-based drug discovery.